(Q52169306)

26 April 2018

title

PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects. (English)

1 reference

26 April 2018

author name string

Corbin AE

1

1 reference

26 April 2018

Meltzer LT

2

1 reference

26 April 2018

Ninteman FW

3

1 reference

26 April 2018

Wiley JN

4

1 reference

26 April 2018

Christoffersen CL

5

1 reference

26 April 2018

Wustrow DJ

6

1 reference

26 April 2018

Wise LD

7

1 reference

26 April 2018

Pugsley TA

8

1 reference

26 April 2018

Heffner TG

9

1 reference

26 April 2018

publication date

1 April 2000

1 reference

26 April 2018

published in

Neuropharmacology

1 reference

26 April 2018

volume

39

1 reference

26 April 2018

issue

7

1 reference

26 April 2018

page(s)

1211-1221

1 reference

26 April 2018

PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Dopamine and the Pathophysiology of Dyskinesias Induced by Antipsychotic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Serotonin-dopamine antagonists and treatment of negative symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

5-HT1A receptor agonists: recent developments and controversial issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Dopamine D3 receptor mRNA and binding sites in human brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Antidepressant-like behavioral effects of serotonin receptor agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

The dopamine hypothesis of schizophrenia: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Selective, centrally acting serotonin 5-HT2 antagonists. 1. 2- and 6-substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

CNS dopamine autoreceptors: distribution, pharmacology, and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Serotonin agents in anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Evidence for specific interactions between 5-HT1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

Aminopyrimidines with high affinity for both serotonin and dopamine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2899%2900214-2

10.1016/S0028-3908(99)00214-2

7 January 2021

Identifiers

DOI

1 reference

26 April 2018

PubMed ID

10760363

1 reference

26 April 2018